RNA, (Am-sp-(2?-deoxy-2?-fluoro)G-sp-Am-Um-Am-Gm-(3??3?)-[1-de-?-D-ribofuranosyl-1-[(2S)-2,3-dihydroxypropyl]]m5U-(2??5?)-Cm-Cm-Am-Um-Gm-Cm-(2?-deoxy-2?-fluoro)A-Am-(2?-deoxy-2?-fluoro)A-Am-Gm-Cm-Am-Um-sp-Um-sp-Cm), complex with RNA (Am-sp-Um-sp-Gm-Cm-Um-Um-(2?-deoxy-2?-fluoro)U-Um-(2?-deoxy-2?-fluoro)G-(2?-deoxy-2?-fluoro)C-(2?-deoxy-2?-fluoro)A-Um-Gm-Gm-Am-Cm-Um-Am-Um-Cm-Um) 3?-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-?-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-?-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1)
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Regeneron Pharmaceuticalsnucleic_acidPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
130 Active assets in the Metabolic Dysfunction-Associated SteatoHepatitis (MASH) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Resmetirom City University of New York | Phase 4 | BBB |
Pentoxifylline Al-Azhar University | Phase 4 | BBB |
Pioglitazone Badr University | Phase 4 | BBB |
Semaglutide Cascade Pharmaceuticals, Inc | Phase 4 | BBB |
Firsocostat Gilead Sciences | Phase 2 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →